2024-11-15 - Analysis Report
## Thermo Fisher Scientific Inc. (TMO) Stock Analysis

**Company Overview:** Thermo Fisher Scientific Inc. is a leading provider of scientific instruments, consumables, and services for research, healthcare, and industrial markets.

**Performance Analysis:**

**1.  Performance vs. S&P 500 (VOO):**

*   **Cumulative Return:** TMO: 216.38%, VOO: 179.47%
*   **Outperformance:** TMO has outperformed the S&P 500 by **36.91%** in terms of cumulative return.
*   **Relative Outperformance:**  Currently, TMO's outperformance is in the **20.39th percentile** compared to its historical outperformance range. 

**Alpha and Beta Analysis:**

*   **Alpha:** TMO exhibits a consistently positive alpha over the past few years, indicating that it has outperformed the market benchmark by a considerable margin. 
*   **Beta:** TMO generally shows a beta slightly above 1, suggesting it is slightly more volatile than the market but has historically provided above-average returns. 

**2. Recent Price Movement:**

*   **Closing Price:** $541.9 (Last Market: $534.69)
*   **5-Day Moving Average:** $547.44
*   **20-Day Moving Average:** $561.96
*   **60-Day Moving Average:** $593.04

TMO is currently trading below its 5-, 20-, and 60-day moving averages, indicating a potential downtrend in the short term.

**3. Technical Indicators:**

*   **RSI:** 36.5 (Below 50, suggesting that the stock is oversold)
*   **PPO:** -0.11 (Negative value, indicating a potential downtrend)
*   **Delta_Previous_Relative_Divergence:** -17.23 (Short-term downtrend)
*   **Expected Return:** 10.73% (Based on historical data, TMO is expected to provide a 10.73% higher return than the S&P 500 over the long term, if invested with a 2-year or more time horizon.)

**4. Recent Earnings and Outlook:**

| Date       | EPS   | Revenue     |
|------------|-------|-------------|
| 2024-11-01 | 4.26  | $10.60 B$  |
| 2024-08-02 | 4.05  | $10.54 B$  |
| 2024-05-03 | 3.47  | $10.35 B$  |
| 2023-11-03 | 4.44  | $10.57 B$  |
| 2024-11-01 | 4.44  | $10.57 B$  |

TMO has consistently reported strong earnings and revenue growth in recent quarters. 

**5.  Financial Information:**

**Revenue and Profitability:**

| Quarter     | Revenue     | Profit Margin |
|-------------|-------------|--------------|
| 2024-09-30 | $10.60B    | 40.84%       |
| 2024-06-30 | $10.54B    | 41.24%       |
| 2024-03-31 | $10.35B    | 40.65%       |
| 2023-12-31 | $10.89B    | 40.35%       |
| 2023-09-30 | $10.57B    | 40.82%       |

**Capital and Profitability:**

| Quarter     | Equity      | ROE          |
|-------------|-------------|--------------|
| 2024-09-30 | $48.99B    | 3.33%        |
| 2024-06-30 | $47.43B    | 3.26%        |
| 2024-03-31 | $45.52B    | 2.92%        |
| 2023-12-31 | $46.73B    | 3.49%        |
| 2023-09-30 | $45.33B    | 3.78%        |

TMO demonstrates consistent profitability, with strong revenue and profit margins. Its capital structure appears solid, with a stable level of equity and a consistent return on equity.

**6. News and Recent Events:**

*   **Recent Earnings:** TMO recently reported strong Q3 2024 earnings, exceeding analyst expectations on both revenue and earnings per share. This positive news is likely to bolster investor sentiment.
*   **Market Outlook:** Recent market sentiment towards TMO remains positive.  Analysts are optimistic about the company's long-term growth prospects, citing strong demand for its products and services in the healthcare and research sectors.
*   **Analyst Opinions:**  Most analysts are bullish on TMO with a consensus "Buy" rating.  Several have recently upgraded their price targets, highlighting the company's strong fundamentals and growth potential.  

**7. Overall Analysis:**

TMO is a fundamentally strong company with a consistent track record of growth and profitability. The recent earnings report reinforces its positive outlook.  While short-term technical indicators suggest a potential downtrend, long-term investors may find it an attractive opportunity due to its above-average historical returns, strong financial position, and positive analyst sentiment.

**Disclaimer:** This analysis is for informational purposes only and is not intended as financial advice. Consult with a qualified financial advisor before making any investment decisions. 
